The company organized all units to study in Jinma Cement Plant
Release time:
2020-07-22
Company organized all units to study
in Jinma Cement Plant. News from our newspaper to find gaps in comparison with the advanced and promote standardization work. 10# September 11 , 16 , the Safety Management Office of the Group Company organized members of the production unit team and safety supervisors in Jinhua to visit Jinma Cement Plant in batches to learn on-site management experience.
Jinma Cement Factory is an old enterprise with a history of more than 20 years. The basic hardware conditions are poor. However, through the technological innovation and management reform in the past two years, the original equipment and equipment have been transformed and upgraded. A messy grinding factory has become a neat, clean and safe civilized factory, 2018 The plant passed the first-level enterprise review of safety standardization. It is understood that in the past two years, the factory has also carried out a substantial personnel optimization, but the output is at a record high. At present, the daily grinding cement reaches more than 22 5000 tons.
Visitors visited the cement production sites such as the power distribution duty room, tool and material storage room, high and low voltage power distribution room, ball mill, etc. of Jinma Cement Plant. The cement floor was smooth and clean. The surface of the old equipment was treated with rust removal and spraying. There were no sundries in the room, no water on the floor, no ash leakage in the pit, no oil leakage in the equipment, and fixed storage of office furniture, orderly, stairs, equipment isolation fence and platform are standardized design.
The two sides also exchanged management experience on site management methods, standards, requirements, and ideological changes. The relevant person in charge of the Golden Horse Factory said, first of all, ideologically, leaders should have the subjective determination to carry out the one-vote veto system for safe and civilized production in the appointment of cadres, and the other is the top-down "forcing " and self-constantly raising the standard requirements. In terms of specific practices, strict standards, multi-technical assistance, leaders lead teams to conduct more assessments, and reward more. The construction of a clean and tidy factory, through technological innovation, has eliminated the problems of production line running, dripping and leakage, reduced the workload of employees, and truly realized personnel optimization and post optimization.
This visit made the visitors of various enterprises really feel the civilized production level of an old cement enterprise. Compared with the past, the appearance of the production site has undergone a radical improvement, which is for the civilized production and standardization of various enterprises. The construction work has a good reference significance. After the visit, the relevant person in charge of the safety management office of the group company hopes that each enterprise will organize discussions, form ideas, make plans, and come up with solutions, truly change ideas into action requirements, and carry out civilized production and standardization work in a down-to-earth manner. (Li Xiaoyin Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31